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During the global outbreak of severe acute respiratory
syndrome (SARS) in 2003, treatment was empiric. We
report the case history of the index patient in a hospital out-
break of SARS in Hong Kong. The patient recovered after
conventional antimicrobial therapy. Further studies are
needed to address treatment of SARS, which has high
attack and death rates.
S
evere acute respiratory syndrome (SARS), a new dis-
ease that is highly contagious, has caused a major
impact worldwide. Treatment of this disease remains
empiric. This report describes the natural history of a case
of SARS in a young, previously healthy patient who
received no specific therapy for infection with SARS-asso-
ciated coronavirus (SARS-CoV). He was the index patient
in a large hospital outbreak in Prince of Wales Hospital in
Hong Kong (1).
Case Report
In early March 2003, a 26-year-old man was admitted
to a general medical ward of the Prince of Wales Hospital;
he had been ill for 1 week with fever, chills, and rigor. He
had had a cough productive of whitish sputum for 2 weeks.
He also had diarrhea and had vomited several times before
his admission. His previous health had been good, and he
had no history of recent travel. Physical examination
showed a temperature of 40.2°C and bronchial breath
sounds at the right upper zone lung field. Chest x-ray con-
firmed right upper lobe consolidation (Figure, part A). 
Acomplete blood profile on admission showed a leuko-
cyte count 3.1 x 109/L, absolute neutrophil count 2.0 x
109/L, lymphocyte count 0.7 x 109/L, platelet count 112 x
109/L, and hemoglobin 14.7 g/dL. The patient had mild
renal impairment, with a creatinine of 119 µmol/L, urea and
electrolytes within normal limits, and alanine transaminase
mildly elevated at 90 IU/L (normal <58 IU/L). Bilirubin,
alkaline phosphatase, and albumin levels were normal. C-
reactive protein was 6.5 mg/L(normal <9.9 mg/L).  Adiag-
nosis of atypical or viral pneumonia was suspected because
of the low leukocyte count and normal C-reactive protein.
Other laboratory tests were performed, including blood,
sputum, and urine cultures, nasopharyngeal aspirate for
influenza and parainfluenza, indirect immunofluorescence
for respiratory syncytial viral antigen detection, and atypi-
cal pneumonia titer (for adenovirus, Chlamydia psittaci, Q
fever, influenza A and B, and Mycoplasma). The patient
received treatment with intravenous amoxicillin-clavu-
lanate and oral clarithromycin.
The patient was housed in a general medical ward with
no specific isolation facility. After admission his high fever
and productive cough, now with thick, yellowish sputum,
persisted. He also complained of progressive dyspnea,
headache, dizziness, generalized malaise, and myalgia. His
pulse and blood pressure were normal, and his oxygen sat-
uration was approximately 98% on room air. Asputum cul-
ture yielded normal oral flora, and sputum smears were
negative for acid-fast bacilli. Nasopharyngeal aspiration
was negative for influenza viruses A and B, respiratory
syncytial virus, adenovirus, and parainfluenzavirus types
1, 2, and 3, with the use of commercial immunofluores-
cence assay. A chest radiograph on day 4 showed progres-
sion of pneumonia, with consolidation changes over the
right upper and lower lobes (Figure, part B). Arepeat com-
plete blood profile showed a leukocyte count of 5.4 x 109/L
with persistent lymphopenia and a platelet count of 98 x
109/L. Amoxicillin-clavulanate was therefore changed to
intravenous cefotaxime, 1 g every 8 h; clarithromycin (500
mg twice a day) was continued. As the patient’s condition
deteriorated progressively and he had difficulty in expec-
torating sputum, salbutamol, 0.5 g four times a day, driven
by a jet nebulizer at 6 L of oxygen per min, was given to
assist mucociliary clearance. His oxygen saturation
remained normal without supplemental oxygen.
Starting from day 6, the patient’s fever and chest condi-
tion gradually improved. However, over the next 2 weeks,
138 persons (mostly healthcare workers) who had been in
contact with him had onset of a similar illness with high
fever and pneumonia. The patient was subsequently con-
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of SARS (1). Three family members were also infected.
Further history showed that he had visited a hotel in
Kowloon, Hong Kong, where a 64-year-old physician
from southern China had stayed for 2 days; this physician
later died of severe atypical pneumonia 10 days after
admission to a regional hospital in Kowloon (2). The cause
of the illness was not known at the time of the physician’s
death. 
Our patient was identified as the index case-patient 5
days after the onset of this large outbreak at the Prince of
Wales Hospital, as he was the first patient who had the
characteristic clinical, radiologic, and laboratory features
of SARS and had epidemiologic links with other infected
persons. After 8 days, use of the nebulized bronchodilator
was stopped because of the possibility of enhancing SARS
transmission, and the patient was isolated in a private room
with negative-pressure ventilation. Healthcare workers
entering the room wore disposable gloves and N95 masks.
After the patient completed a 7-day course of cefotaxime
and a 10-day course of clarithromycin, his pneumonia
recovered gradually, and serial chest radiographs con-
firmed resolution of his consolidation (Figure, part C). His
diarrhea and other systemic symptoms also resolved spon-
taneously. 
An immunofluorescence test for antibody against
SARS-CoV subsequently confirmed an elevated titer of
1:5,120 in convalescent-phase serum collected on day 21
of illness. Polymerase chain reaction of nasopharyngeal
aspirate was negative for coronavirus. Convalescent-phase
serum was negative for other atypical pneumonia organ-
isms, including adenovirus, C. psittaci, Q fever, influenza
A and B, and Mycoplasma. Repeat complete blood count
showed that lymphocytes and thrombocytes had returned
to normal, along with serum creatinine and alanine
transaminase levels. 
The patient was isolated in a private room until day 27
of his hospital stay, when his nasopharyngeal aspirate and
urine samples were confirmed to be negative for SARS-
CoV. Repeat chest radiograph at follow-up 2 weeks later
showed no residual parenchymal opacity, and the patient
remained asymptomatic.
Conclusions
This report describes the index patient responsible for
the hospital outbreak in the Prince of Wales Hospital (2).
He was linked to spread of the virus to more than 100 per-
sons (1). This outbreak, together with similar events in
Canada (3), Singapore (4) and other cities where the
source of infection was also related to the Chinese physi-
cian (5), led to increased awareness of this emerging glob-
al infection caused by a novel coronavirus (6).The super-
spread event in Prince of Wales Hospital caused by this
340 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 2, February 2004
EMERGENCE OF SARS
Figure. Chest radiographs performed A, at admission, B, on day 4,
and C, on day 16 of hospitalization for index SARS case-patient,
Prince of Wales Hospital.
A
B
Cpatient was related to failure to apply isolation precautions,
as the disease had not been recognized during the early
part of his admission. The use of a nebulized bronchodila-
tor may also have enhanced the spread of the virus in the
ward, and this practice was stopped for patients with sus-
pected SARS after this incident (7). 
This case report illustrates the natural history of SARS
in a young, previously healthy patient who received no
specific therapy. His clinical features and laboratory
parameters were similar to those of other patients with
SARS (2–5). His clinical course followed a typical pattern
with progression of pneumonia during the 2nd week of his
illness (8). He was treated presumptively for bacterial
community-acquired pneumonia with conventional
antimicrobials (9), without antiviral agents or corticos-
teroids. He started to improve by the 3rd week and subse-
quently recovered uneventfully. 
During the global outbreak in 2003, treatment of SARS
was empiric. Several groups have reported the use of rib-
avirin (2–5,7,8) and corticosteroids (2,3,7,8,10,11) with
generally favorable outcomes. Ribavirin has been associat-
ed with substantial adverse reactions, including hemolytic
anemia, elevated transaminases, and bradycardia (4), and
has demonstrated no in vitro activity against SARS-CoV
(12).Further studies, preferably with a randomized, place-
bo-control design, are needed to address treatment of this
disease, which has high attack rates and is frequently fatal.
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